Anti-heparin activity of lysosomal cationic proteins from polymorphonuclear leukocytes.
D000925:Anticoagulants / Q000032:analysis; D000991:Antithrombins / Q000037:antagonists & inhibitors; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D001798:Blood Proteins / Q000502:physiology; D005340:Fibrinogen / Q000502:physiology; D006003:Glycogen / Q000494:pharmacology; D006494:Heparin Antagonists / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007274:Injections, Intraperitoneal; D007962:Leukocytes / Q000032:analysis*; D008247:Lysosomes / Q000032:analysis*; D008722:Methods; D009504:Neutrophils / Q000502:physiology; D010406:Penicillins / Q000627:therapeutic use; D010714:Phosphatidylethanolamines / Q000502:physiology; D010743:Phospholipids; D011506:Proteins / Q000494:pharmacology*; D013307:Streptomycin / Q000627:therapeutic use; D013917:Thrombin / Q000502:physiology
D000925:Anticoagulants; D000991:Antithrombins; D001798:Blood Proteins; D006494:Heparin Antagonists; D010406:Penicillins; D010714:Phosphatidylethanolamines; D010743:Phospholipids; D011506:Proteins; D005340:Fibrinogen; D006003:Glycogen; D013917:Thrombin; D013307:Streptomycin